Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19

Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($1.19), versus ($1.01) reported last year. Revenue for the quarter came in at $296 thousand, versus $222 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Deere shares climb as fiscal Q3 earnings and revenue top estimates
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth